Currently Viewing:
Supplements Sickle Cell Disease: Current Treatment and Emerging Therapies
Sickle Cell Disease: Current Treatment and Emerging Therapies
Lynne D. Neumayr, MD; Carolyn C. Hoppe, MD, MPH; Clark Brown, MD, PhD
Currently Reading
Participating Faculty

Participating Faculty

FACULTY

Clark Brown, MD, PhD
Associate Professor, Department of Pediatrics
Emory University School of Medicine
Director, Sickle Cell Program
Aflac Cancer and Blood Disorders Center
Children’s Healthcare of Atlanta
Atlanta, GA

Carolyn Hoppe, MD, MPH
Global Blood Therapeutics
South San Francisco, CA

Lynne D. Neumayr, MD
Professor of Pediatrics
Division of Hematology/Oncology
UCSF Benioff Children’s Hospital Oakland
Oakland, CA

FACULTY DISCLOSURES
These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

Clark Brown, MD, PhD
CONSULTANCIES OR PAID ADVISORY BOARDS
Global Blood Therapeutics,  Novartis, Imara, Inc
GRANTS RECEIVED
Global Blood Therapeutics, Novartis, Imara, Inc.
LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR
Global Blood Therapeutics, Imara, Inc

Carolyn C. Hoppe, MD, MPH
EMPLOYMENT
Global Blood Therapeutics
STOCK OWNERSHIP
Global Blood Therapeutics

Lynne D. Neumayr, MD
CONSULTANCIES OR PAID ADVISORY BOARDS
ApoPharma, Inc.
GRANTS RECEIVED
Global Blood Therapeutics, Imara, Inc, La Jolla Pharmaceutical, Protagonist Therapeutics, Bluebird Bio, Sangamo Therapeutics, Pfizer, Bioverative Therapeutics, Inc., Cerus Corporation, Micelle Biopharma, Inc.
GRANTS PENDING
Novartis



 
PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up